Form 4 · Filed Jun 12, 2026, 09:09 PM UTC
SNDX/Syndax Pharmaceuticals Inc
Botwood Nicholas A.J. — Head of R&D, CMO
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
6 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 12, 2026 | M | other | 31,235 | $14 | $431,668 | 92,120 |
| Jun 12, 2026 | S | sell | 31,235 | $18 | $566,603 | 60,885 |
| Jun 12, 2026 | M | other | 31,235 | — | — | 0 |
| Jun 11, 2026 | M | other | 22,515 | $14 | $311,157 | 95,165 |
| Jun 11, 2026 | S | sell | 34,280 | $18 | $617,040 | 60,885 |
| Jun 11, 2026 | M | other | 22,515 | — | — | 0 |
Source: SEC EDGAR raw filing ↗ · Accession 0001193125-26-269694